Browse News
Filter News
Found 757,020 articles
-
Tuesday, de-extinction company Colossal Biosciences closed a mammoth, $150 million Series B financing round and announced plans to resurrect the iconic Dodo – extinct since the 17th century.
-
uniQure inked a deal with Apic Bio to gain development and commercialization rights to APB-102, a gene therapy for a rare, genetic form of ALS.
-
Pfizer reported full-year 2022 earnings Tuesday and provided 2023 projections far below the previous year's totals.
-
The pharmaceutical industry is expected to spend more than $3 billion on artificial intelligence by 2025, but advocates say it is not yet living up to its potential.
-
Follow along as BioSpace keeps you up-to-date on which companies are tightening their belts and cutting staff throughout 2023.
-
No Ph.D., No Problem: BioPharma Companies Welcome Candidates with Only a Bachelor’s Degree
1/31/2023
Now more than ever, there is ample opportunity for life science candidates with only a bachelor's degree. Still, there are certain things these candidates should know to ensure their success. -
SeaStar Medical to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023
1/31/2023
SeaStar Medical announces that Eric Schlorff, CEO, will present a company overview at the virtual Sequire Biotechnology Conference on Thursday, February 2 at 3:30 p.m. Eastern time.
-
scPharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
1/31/2023
scPharmaceuticals Inc. announced that John Tucker, President & Chief Executive Officer, is scheduled to present virtually at the SVB Securities Global Biopharma Conference, on Thursday, February 16 at 11:20 am ET.
-
Endonovo Retains Ocean Tomo, a Part of J.S. Held, to Provide Fairness Opinion Analysis for Medical Device Spin-Off
1/31/2023
Endonovo Therapeutics, Inc. announced the retention of Ocean Tomo, a part of J.S. Held, to conduct a fairness opinion analysis in connection with the proposed spin-off of Endonovo’s medical device assets to a newly formed Delaware company, SofPulse, Inc.
-
AB Science announces the drawdown of the second tranche of 6 million euros under its financing agreement with the European Investment Bank
1/31/2023
AB Science SA announced that it has received payment of €6.0 million as the second tranche of a €15 million loan from the European Investment Bank.
-
ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) Patients
1/31/2023
ChromaDex Corp. announced promising findings from a first-of-its kind clinical study, as reported in the peer-reviewed journal Translational Neurodegeneration by a team of scientists led by Dr. Adil Mardinoglu.
-
Biological Dynamics, Perlmutter Cancer Center at NYU Langone Health collaborate on pancreatic cancer research
1/31/2023
Biological Dynamics, a company commercializing its exosome-isolation ExoVerita™ platform, announced a collaboration with the Perlmutter Cancer Center at NYU Langone Health to validate its application for the early detection of pancreatic ductal adenocarcinoma.
-
UTMD Reports Audited Year 2022 and Fourth Quarter Financial Performance
1/31/2023
Utah Medical Products, Inc. finished the calendar year with a solid fourth quarter performance, which allowed financial results for the year 2022 exceeding management’s beginning of year projections, despite many challenges.
-
CLS Americas and URN Announce Treatment of 20th & Final Patient in Clinical Study “Targeted MRI/ US Fusion Transperineal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer”
1/31/2023
CLS Americas announced the full twenty patients have been safely treated in the previously announced Phase I clinical study titled, “Targeted MRI/US Fusion Transperineal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer.”
-
Gregory Basil MD to Join Aclarion as a Key Opinion Leader Surgeon Advisor
1/31/2023
Aclarion, Inc.,a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced that Gregory Basil, MD, Director of Endoscopic Spine Surgery at the University of Miami will advise the company as a key opinion leader.
-
Arcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis
1/31/2023
Arcturus Therapeutics Holdings Inc. today announced that the Clinical Trial Application (CTA) for ARCT-032, an inhaled investigational mRNA medicine to treat cystic fibrosis (CF), received approval to proceed into a Phase 1 First-in-Human study in New Zealand.
-
Mirion Technologies Announces Earnings Release and Conference Call Date for Fourth Quarter and Fiscal Year 2022 Results
1/31/2023
Mirion Technologies, Inc. announced that it will release its financial results for the fourth quarter and fiscal year 2022 on Tuesday, February 14, 2023.
-
Eyenovia Showcases Microdose Array Print (MAP™) Technology at CES 2023 in Las Vegas
1/31/2023
Eyenovia, Inc., a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, showcased the Microdose Array Print Technology at CES 2023 in Las Vegas, Nevada, from Jan. 5-8.
-
COTA, Inc. Forms Strategic Real-World Data Research Partnership with the Clinical Research Data Sharing Alliance
1/31/2023
COTA, Inc.today announced its membership in the Clinical Research Data Sharing Alliance (CRDSA), a nonprofit, cross-industry alliance of biopharma companies, data sharing platforms, academic institutions, and service and technology partners.
-
MicroTransponder Secures CMS Transitional Pass-Through Status & New Technology Add-On Payment for Its Breakthrough Stroke Rehabilitation System, Vivistim
1/31/2023
MicroTransponder®, Inc. announces that the Centers for Medicare and Medicaid Services awarded the Vivistim® Paired VNS™ System transitional pass-through status, expanding access to Medicare beneficiaries who are ischemic stroke survivors interested in using the breakthrough technology to help improve their hand and arm mobility.